📊 TWST Key Takeaways
Is Twist Bioscience Corp (TWST) a Good Investment?
Twist Bioscience demonstrates solid 20.3% revenue growth in a capital-intensive biotech sector but faces significant operational headwinds with -36.7% operating margins and -$60.2M annual free cash flow burn. The company's fortress balance sheet (zero meaningful debt, $122.7M cash, 2.70x current ratio) provides 2+ year runway, but path to profitability remains unclear with continuing $78.8M operating losses on $214.4M revenue.
Why Buy Twist Bioscience Corp Stock? TWST Key Strengths
- Strong revenue growth momentum at 20.3% YoY in competitive biotech sector
- Pristine balance sheet with zero debt, $122.7M cash, and 2.70x current ratio enabling financial flexibility
- Improving loss metrics with 63.9% YoY EPS improvement indicates operational progress toward breakeven
TWST Stock Risks: Twist Bioscience Corp Investment Risks
- Severe operating losses consuming $78.8M (-36.7% margin) on $214.4M revenue with no path to profitability visible
- Negative free cash flow of $60.2M annually creates finite runway of ~2 years at current burn rate
- R&D-intensive biological products sector requires sustained capital investment to maintain competitive position
Key Metrics to Watch
- Operating margin trajectory - critical inflection toward positive territory needed
- Free cash flow sustainability - when does operating cash flow turn positive?
- Gross margin (unreported) - essential for assessing underlying unit economics and pricing power
- Cash runway depletion rate - with $122.7M cash and -$60.2M FCF, timeline to cash shortage
Twist Bioscience Corp (TWST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.70x current ratio provides a solid financial cushion.
TWST Profit Margin, ROE & Profitability Analysis
TWST vs Healthcare Sector: How Twist Bioscience Corp Compares
How Twist Bioscience Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Twist Bioscience Corp Stock Overvalued? TWST Valuation Analysis 2026
Based on fundamental analysis, Twist Bioscience Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Twist Bioscience Corp Balance Sheet: TWST Debt, Cash & Liquidity
TWST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Twist Bioscience Corp's revenue has grown significantly by 185% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.60 indicates the company is currently unprofitable.
TWST Revenue Growth, EPS Growth & YoY Performance
TWST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $92.8M | -$39.3M | $-0.66 |
| Q1 2026 | $88.7M | -$30.5M | $-0.50 |
| Q3 2025 | $81.5M | $20.4M | $0.33 |
| Q2 2025 | $75.3M | -$39.3M | $-0.66 |
| Q1 2025 | $71.5M | -$31.6M | $-0.53 |
| Q3 2024 | $63.7M | -$57.4M | $-1.01 |
| Q2 2024 | $60.2M | -$45.5M | $-0.79 |
| Q1 2024 | $54.2M | -$41.8M | $-0.74 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Twist Bioscience Corp Dividends, Buybacks & Capital Allocation
TWST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Twist Bioscience Corp (CIK: 0001581280)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TWST
What is the AI rating for TWST?
Twist Bioscience Corp (TWST) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TWST's key strengths?
Claude: Strong revenue growth momentum at 20.3% YoY in competitive biotech sector. Pristine balance sheet with zero debt, $122.7M cash, and 2.70x current ratio enabling financial flexibility.
What are the risks of investing in TWST?
Claude: Severe operating losses consuming $78.8M (-36.7% margin) on $214.4M revenue with no path to profitability visible. Negative free cash flow of $60.2M annually creates finite runway of ~2 years at current burn rate.
What is TWST's revenue and growth?
Twist Bioscience Corp reported revenue of $214.4M.
Does TWST pay dividends?
Twist Bioscience Corp does not currently pay dividends.
Where can I find TWST SEC filings?
Official SEC filings for Twist Bioscience Corp (CIK: 0001581280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TWST's EPS?
Twist Bioscience Corp has a diluted EPS of $-1.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TWST a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Twist Bioscience Corp has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TWST stock overvalued or undervalued?
Valuation metrics for TWST: ROE of -16.4% (sector avg: 15%), net margin of -34.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TWST stock in 2026?
Our dual AI analysis gives Twist Bioscience Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TWST's free cash flow?
Twist Bioscience Corp's operating cash flow is $-42.4M, with capital expenditures of $17.9M. FCF margin is -28.1%.
How does TWST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34.8% (avg: 12%), ROE -16.4% (avg: 15%), current ratio 2.70 (avg: 2).